SYRE
Spyre Therapeutics, Inc.NASDAQHealthcare$47.58-2.70%ClosedMarket Cap: $2.87B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
23.02
P/S
31.76
EV/EBITDA
-15.56
DCF Value
$0.23
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-231.6%
Net Margin
-171.5%
ROE
-29.4%
ROA
-20.0%
ROIC
-29.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $90.5M | 50.0% | $-57.2M | $-62.5M | $-0.70 | — |
| FY 2025 | $0.00 | -Infinity% | $-209.6M | $-155.2M | $-1.98 | — |
| Q3 2025 | $0.00 | -Infinity% | $-56.9M | $-11.2M | $-0.15 | — |
| Q2 2025 | $0.00 | NaN% | $-41.9M | $-36.7M | $-0.60 | — |
| Q1 2025 | $0.00 | NaN% | $-53.6M | $-44.8M | $-0.13 | — |
| Q4 2024 | $0.00 | NaN% | $-61.3M | $-56.3M | $-0.15 | — |
| FY 2024 | $0.00 | NaN% | $-208.6M | $-208.0M | $-3.18 | — |
| Q3 2024 | $0.00 | NaN% | $-55.4M | $-69.0M | $-1.36 | — |
| Q2 2024 | $0.00 | NaN% | $-44.1M | $-38.8M | $-0.86 | — |
| Q1 2024 | $0.00 | NaN% | $-47.8M | $-43.9M | $-1.20 | — |
| Q4 2023 | $0.00 | NaN% | $-45.9M | $-63.2M | $-2.91 | — |
| FY 2023 | $886.0K | 100.0% | $-242.3M | $-338.8M | $-46.15 | — |